Sheldon Sloan, the Chief Medical Officer of $SYRE, sold 8,333 shares of the company on 06-03-2026 for an estimated $624,975. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares of this class of stock. Following this trade, they now own 0 shares of this class of $SYRE stock.
$SYRE Insider Trading Activity
$SYRE insiders have traded $SYRE stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $SYRE stock by insiders over the last 6 months:
- SHELDON SLOAN (Chief Medical Officer) has made 0 purchases and 9 sales selling 94,624 shares for an estimated $6,623,576.
- CAMERON TURTLE (Chief Executive Officer) has made 0 purchases and 18 sales selling 90,000 shares for an estimated $4,451,950.
- SCOTT L BURROWS (Chief Financial Officer) has made 0 purchases and 8 sales selling 30,000 shares for an estimated $1,896,757.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SYRE Hedge Fund Activity
We have seen 120 institutional investors add shares of $SYRE stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC added 1,839,780 shares (+149.6%) to their portfolio in Q4 2025, for an estimated $60,271,192
- JANUS HENDERSON GROUP PLC added 1,816,009 shares (+13969.3%) to their portfolio in Q4 2025, for an estimated $59,492,454
- CAPITAL INTERNATIONAL INVESTORS removed 1,746,412 shares (-50.0%) from their portfolio in Q1 2026, for an estimated $88,089,021
- JEFFERIES FINANCIAL GROUP INC. removed 1,388,854 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $45,498,857
- TANG CAPITAL MANAGEMENT LLC removed 1,307,800 shares (-40.9%) from their portfolio in Q4 2025, for an estimated $42,843,528
- VR ADVISER, LLC added 1,000,000 shares (+37.2%) to their portfolio in Q4 2025, for an estimated $32,759,999
- VANGUARD GROUP INC added 984,344 shares (+32.3%) to their portfolio in Q4 2025, for an estimated $32,247,109
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$SYRE Analyst Ratings
Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 12/18/2025
To track analyst ratings and price targets for $SYRE, check out Quiver Quantitative's $SYRE forecast page.
$SYRE Price Targets
Multiple analysts have issued price targets for $SYRE recently. We have seen 12 analysts offer price targets for $SYRE in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Alex Thompson from Stifel set a target price of $107.0 on 05/06/2026
- Samantha Semenkow from Citigroup set a target price of $97.0 on 05/06/2026
- Debanjana Chatterjee from Jones Trading set a target price of $95.0 on 04/17/2026
- Colleen Kusy from Baird set a target price of $90.0 on 04/14/2026
- Martin Auster from Raymond James set a target price of $80.0 on 04/14/2026
- David Hoang from Deutsche Bank set a target price of $88.0 on 04/14/2026
- David Nierengarten from Wedbush set a target price of $80.0 on 04/14/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
